2020–2026 Global and Chinese Vitamin K2 Market: Current Status and Future Development Trends

The vitamin K2 industry exhibits a high degree of concentration. Major global manufacturers are primarily located in Europe, Japan, China, and India. Some large enterprises focus solely on marketing vitamin K2—such as J-Oil Mills’ NattoPharma and Frutarom, and DuPont Nutrition & Biosciences (Kappa Bioscience)—all of which market products under registered trademarks. Gnosis leads the natural-product segment, while Kappa dominates the synthetic-product segment. Major consumption markets are in developed countries. Europe accounts for 34.2% of revenue share, followed by North America at 32.8% in 2019. We anticipate the industry is becoming increasingly mature, with consumer growth rates exhibiting a decelerating trend. Marketing Channels Marketing channels vary by company in international markets. Leading international firms prefer to contract with large marketing companies or appoint major regional distributors in key countries and regions to establish their international market presence. In contrast, companies from developing countries such as China and India invest more effort in direct sales. They often simultaneously serve as exporters—a common practice in this industry. Due to their relatively limited international brand influence and comparatively lower product quality versus leading firms, they leverage price advantages to expand market share in developing countries and low-end international markets. Pricing Market dynamics are influenced not only by price but also by product performance. Although smaller companies enjoy pricing advantages, their applications remain relatively narrow due to inferior manufacturing processes, cheaper raw materials, and limited product varieties. Looking ahead, the recent trend of gradual price fluctuations will persist over the next few years. As competition intensifies, price gaps among different brands will narrow, and gross margins will likewise fluctuate. Product Types and Other Factors Vitamin K2 is generally categorized into three types: MK-4, MK-7, and MK-9, among others. MK-4 and MK-7 are widely used globally, especially MK-7, which is mainly produced in Europe, China, and Japan. MK-4 is primarily manufactured in China and Japan. This industry is affected by both economic conditions and policy environments; therefore, monitoring macroeconomic indicators and policymakers’ preferences is essential. With the global economic recovery, increasing attention is being paid to improved living standards—especially in populous, rapidly growing emerging economies—driving rising demand for vitamin K2. Looking forward, the global vitamin K2 market is projected to grow from USD 102.9 million in 2019 to USD 400.8 million by 2026, representing a compound annual growth rate (CAGR) of 21.4% during the forecast period. QYResearch (YanZhou BoZhi) published the report titled "Global and Chinese Vitamin K2 Industry Research Report, 2020–2026, and Analysis under the 14th Five-Year Plan". This report examines the supply and demand of vitamin K2 in global and Chinese markets during the 13th Five-Year Plan period (2016–2020), and forecasts industry development during the 14th Five-Year Plan period (2021–2026). It focuses on analyzing production capacity, output, value, and pricing of vitamin K2 across major global regions—and consumption patterns across major global regions (and countries)—with historical data covering 2015–2020 and forecast data spanning 2021–2026.

Accelerating Market Consolidation in the Vitamin K2 Industry: Top Five Manufacturers Account for Over 75% Share; MK-7 Emerges as the Dominant Product

Vitamin K2 is a lipophilic compound belonging to the menaquinone class within the vitamin K family. Its molecular structure consists of a 2-methyl-1,4-naphthoquinone core and an isoprenoid side chain of varying length, typically designated as MK-n. Commercially available products include MK-7, MK-4, and other menaquinones (e.g., MK-9), among which MK-7 has become the most important commercial form in the global nutrition and health market. Products are obtained either via microbial fermentation or chemical synthesis, and further processed into high-purity powders, microencapsulated powders, oil-based formulations, and standardized ingredient blends. According to QYResearch’s survey and statistics, the global vitamin K2 market size was approximately USD 338.5 million in 2025, and is expected to reach about USD 384 million in 2026, growing to an estimated USD 592.6 million by 2032—with a compound annual growth rate (CAGR) of approximately 7.5% between 2026 and 2032. Key growth drivers include healthy aging, bone health nutrition, combined vitamin D3 + K2 formulations, penetration into functional foods and beverages, and technological advances—including microencapsulation, water-dispersible forms, and novel dosage formats—that broaden application boundaries. In 2025, the top five global vitamin K2 manufacturers collectively held over 75% market share, indicating high industry concentration. Representative leading enterprises include Gnosis (under Lesaffre, integrating NattoPharma), Kappa Bioscience (under Balchem), Guangdong Shuangjun Bio-Technology Co., Ltd., Novonesis, and IFF Health (formerly Frutarom). Competitive focus is shifting from mere raw-material supply toward branded ingredients, all-trans purity, stability of fermentation or synthetic processes, formulation capabilities, regulatory support, and global customer coverage. By molecular subtype, vitamin K2 comprises primarily MK-7, MK-4, and other menaquinones (e.g., MK-9). In 2025, MK-7 accounted for approximately 94% of the global market—making it the absolute mainstream; MK-4 accounted for about 4%, and other subtypes roughly 2%. By application, nutrition applications account for approximately 87%, while food and beverage applications represent about 13%.

Vitamin K2 Market Projected to Reach $339.9 Million by 2031 | Top Players Include Gnosis by Lesaffre and Balchem Corp

Jul 24, 2026

The Vitamin K2 market is projected to reach USD 339.9 million by 2031, driven by demand for bone and cardiovascular health solutions. Key players include Gnosis by Lesaffre, Balchem Corp., and Novonesis A/S, with Asia Pacific set to lead growth.

WKOW

2026-03-22

BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms

2026-03-27

Balchem Reports €0.0 Million NonCurrent Deferred Revenue as of December 2025

2026-04-09

Balchem Corp. Stock Valuation Revised Amid Competitive FMCG Landscape

2026-04-11

Balchem Reports $581 Million Gross Property, Plant and Equipment as of December 2025

2026-04-16

Zinc Methionine Chelates Market Forecast Report 2025-2033 Featuring Alltech, Balchem, Titan Biotech, UNO VETCHEM, Zinpro, Chaitanya Biologicals, Chengdu Chelation Biology, JH, Novus, Priya